<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        5-5098-20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        OCTAPLAS LG 45-70MG/ML
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        PLASMA PROTEIN FRACTION
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        45-70
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        200
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bag
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        As provided in the Drug Summary Bulletin
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        614.10
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="OCTAPHARMA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            OCTAPHARMA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 354]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI INTERNATIONAL TRADING COMPANY LTD (SITCO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            OCTAPHARMA AG
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        B05AA
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>octaplasLG is human plasma pooled and treated for virus inactivation. Human plasma is the<br />fluid part of human blood that carries the cells. It contains human plasma proteins which are<br />important to maintain normal clotting characteristics and is used the same way as normal<br />fresh-frozen plasma (FFP).<br />octaplasLG helps in case of complex deficiencies of coagulation factors which can be caused<br />by severe failure of the liver or massive transfusion. octaplasLG may also be given in emergency<br />situations when a coagulation factor concentrate (such as Factor V or Factor XI) is not available<br />or a necessary laboratory diagnosis is not possible.<br />It may also be given to rapidly reverse the effects of oral anticoagulants (coumarin or<br />indanedione type), when vitamin K is insufficient due to impaired liver function or in<br />emergency situations.<br />octaplasLG can be given to patients who undergo plasma exchange in order to restore the<br />balance of the coagulation factors.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use octaplasLG:</strong><br />- if you are allergic (hypersensitive) to human plasma proteins or any of the other ingredients of this medicine (listed in section 6).<br />- if you know you have antibodies against the immunoglobulin called IgA.<br />- if you had previous reactions to any preparation of human plasma or FFP.<br />- if you know you have a low level of protein S (a Vitamin K dependent protein in your blood).<br /><strong>Warnings and precautions</strong><br />Talk to your doctor before using octaplasLG.<br />Tell your doctor if you have any other illnesses.<br /><strong>Take special care with octaplasLG:</strong><br />- if you have a low level of immunoglobulin A.<br />- if you had previous reactions to plasma protein including FFP.<br />- if you are suffering from heart failure or fluid in the lungs (pulmonary oedema).<br />- if you have known risks for blood clotting (thrombotic) complications because of the<br />potential increased risk of venous thromboembolism (clots forming in your veins).<br />- in case of increased inhibition of coagulation (fibrinolysis).<br />octaplasLG is not generally recommended for the treatment of von Willebrand&rsquo;s Disease.</p><p><u>Virus safety</u><br />When medicines are made from human blood or plasma, certain measures are put in place to<br />prevent infections being passed on to patients. These include careful selection of the blood<br />and plasma donors to make sure those at risk of carrying infections are excluded, and the<br />testing of each donation and pools of plasma for signs of virus/infections. Manufacturers of<br />these products also include steps in the processing of the blood or plasma that can inactivate<br />or remove the viruses. Despite these measures, when medicines prepared from human blood<br />or plasma are administered, the possibility of passing on infection cannot be totally excluded.<br />This also applies to any unknown or emerging viruses or other types of infections.<br />The measures taken are considered effective for enveloped viruses such as human<br />immunodeficiency virus (HIV), hepatitis B virus and hepatitis C virus.<br />The measures taken may be of limited value against certain non-enveloped viruses such as<br />hepatitis A virus, hepatitis E virus and Parvovirus B19.<br />It is strongly recommended that every time you receive a dose of octaplasLG the name and<br />batch number of the product are recorded in order to maintain a record of the batch used.<br />Your doctor may recommend that you consider vaccination against hepatitis A and B viruses if<br />you regularly/repeatedly receive human plasma-derived products.</p><p>&nbsp;</p><p><strong>Children</strong><br />The experience in children is limited.<br /><strong>Other medicines and octaplasLG</strong><br />During clinical trials, octaplasLG has been administered in combination with various other<br />medications, and no interactions have been identified.<br />octaplasLG may not be mixed with other intravenous fluids or medicines except red blood cells<br />and blood platelets.<br />To avoid the possibility of blood clots, solutions containing calcium must not be administered<br />by the same intravenous pathway as octaplasLG.<br />There are no known reactions with other drugs.<br />Tell your doctor if you are taking or have recently taken any other medicines, including<br />medicines obtained without a prescription.<br /><strong>octaplasLG with food and drink</strong><br />No effects have been observed.</p><p><strong>Pregnancy, breast-feeding and fertility</strong><br />If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a<br />baby, ask your doctor for advice before taking this medicine. You will only be given octaplasLG<br />if your doctor considers it important for you.<br /><strong>Driving and using machines</strong><br />No effect has been observed upon the ability to drive or operate machinery. You alone are<br />responsible to decide if you are in a fit condition to drive a motor vehicle or perform other tasks<br />that demand increased concentration.<br /><strong>Important information about some of the ingredients of octaplasLG</strong><br />For a list of ingredients please refer to section 6.<br />This medicine contains maximum 920 mg sodium (main component of cooking/table salt) in<br />each bag. This is equivalent to maximum 46% of the recommended maximum daily dietary<br />intake of sodium for an adult.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>octaplasLG will be given to you by a doctor or nurse. It is given by an infusion into your veins.<br />Your dosage depends upon your clinical situation and your body weight. Your doctor will<br />determine the appropriate amount that you should receive.<br />- Before octaplasLG can be given to you by infusion an ABO-blood group compatibility test<br />must be performed.<br />- In emergency cases, octaplasLG blood group AB can be given to all patients.<br />It is important that the infusion rate should not exceed 1 mL octaplasLG per kg of your<br />body weight per minute. Calcium gluconate may be given into another vein to minimise the<br />negative effects of the citrate contained in octaplasLG.<br />You should be observed during and at least for 20 minutes after the administration in case you<br />develop an allergic reaction (anaphylactic reaction) or shock, in which case the infusion must<br />be stopped immediately.<br /><strong>If you use more octaplasLG than you should</strong><br />High dosages may lead to fluid overload, fluid in lungs and/or heart problems.<br /><strong>If you forget to use octaplasLG</strong><br />Your doctor is responsible to supervise administration and to keep your laboratory values<br />within the specified range.<br /><strong>If you stop using octaplasLG</strong><br />Based on laboratory values your doctor decides when to stop administration of octaplasLG<br />and will assess possible risks.<br />Do not use after the expiry date given on the label.</p><p><strong>There are several options for thawing frozen octaplasLG:</strong><br />- Water bath:<br />Thaw in the outer wrapper for not less than 30 minutes in a circulating water bath<br />at +30&deg;C to +37&deg;C. An overwrap bag may be used to provide further protection of<br />contents if appropriate.<br />Prevent water from contaminating the entry port. The minimum thawing time is 30<br />minutes at 37&deg;C. Temperature in the water bath must never exceed +37 &deg;C and should<br />not be lower than +30 &deg;C.<br />The thawing time depends on the number of bags in the water bath. If more plasma<br />bags are thawed in parallel, the thawing time can be prolonged, but should not be<br />longer than 60 minutes.<br />- Using a dry tempering system such as the SAHARA-III:<br />Place the octaplasLG bags on the agitation plate according to the manufacturer<br />instructions and thaw plasma using the fast tempering function. When a +37&deg;C<br />blood component temperature is indicated on the temperature display, terminate the<br />tempering process and remove the bags.<br />During thawing of octaplasLG using a dry tempering system, it is recommended to use<br />the protocol printer to record the course of the blood component temperature and error<br />messages in event of failure.<br />- Others:<br />Other thawing systems for frozen octaplasLG can be used on the condition that the<br />methods are validated for that purpose.<br />Allow the content of the bag to warm to approximately +37 &deg;C before infusion. The<br />temperature of octaplasLG must not exceed +37 &deg;C. Remove the outer wrapper and examine<br />the bag for cracks or leaks.<br />Avoid shaking.</p><p>After thawing the solution is clear to slightly opalescent and free of solid or gelatinous particles.<br />Do not use solutions which are cloudy or have deposits and/or discoloration.<br />Thawed octaplasLG must not be refrozen. Unused product must be discarded.<br />Any unused medicinal product or waste material should be disposed of in accordance with<br />local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.<br />Hypersensitivity reactions may rarely be observed. These are usually mild allergic type reactions<br />consisting of localised or generalised reddening of the skin, hives or itching. More severe<br />forms can be complicated by drop in blood pressure or swelling of the face or tongue. Severe<br />whole-body allergic reactions may have a rapid onset and may be serious. Symptoms are<br />drop in blood pressure, increase in heart rate, difficulty in breathing, wheezing, coughing,<br />breathlessness, nausea, vomiting, diarrhoea, abdominal or back pain. Severe reactions may<br />proceed to shock, unconsciousness, respiratory failure and very rarely even death.<br />Negative effects can be caused by the citrate contained in octaplasLG and the related low<br />calcium level especially if the infusion rate is high, if you have liver function disorders or if you<br />are undergoing plasma exchange procedures. You may experience symptoms like fatigue,<br />tingling feelings (paraesthesia), tremor and low calcium levels.<br />octaplasLG may increase the risk of blood clots in veins of the:<br />&bull; limbs, causing pain and swelling of limbs;<br />&bull; lung, causing chest pain and breathlessness;<br />&bull; brain, causing weakness and/or loss of sensation down one side of the body;<br />&bull; heart, causing chest pain;<br />In all patients at risk for increased clotting of the blood special caution should be exercised and<br />appropriate measures should be considered.<br />Rarely, incompatibility between antibodies in octaplasLG and antigens in your blood can result<br />in destruction of your red blood cells (haemolytic transfusion reactions). Symptoms are chills;fever; a non-productive cough; difficulty in breathing; rash; and bleeding within the body.<br />Infusion of octaplasLG may give rise to specific coagulation factor antibodies.<br />High dosages or infusion rates may induce increased blood volume; fluid in the lungs and/or<br />heart failure.<br />During clinical trials with octaplasLG&rsquo;s predecessor product, and its post-approval use, the<br />following side effects have been identified:</p><table border="1" cellspacing="1" cellpadding="1" style="width:522px"><tbody><tr><td style="width:112px"><p>system organ class</p></td><td style="width:105px">common (&ge;1/100 to&nbsp;&lt; 1/10 or<br />&ge; 1% to<br />&lt; 10%)</td><td style="width:96px">Uncommon<br />(&ge; 1/1,000<br />to<br />&lt; 1/100 or<br />&ge; 0.1% to<br />&lt; 1%)</td><td style="width:104px">Rare<br />(&ge; 1/10,000<br />to<br />&lt; 1/1,000 or<br />&ge; 0.01% to<br />&lt; 0.1%)</td><td style="width:104px">Very rare<br />(&lt; 1/10,000 or<br />&lt; 0.01%)</td></tr><tr><td style="width:112px"><p>Blood system<br />disorders</p></td><td style="width:105px">&nbsp;</td><td style="width:96px">&nbsp;</td><td style="width:104px">&nbsp;</td><td style="width:104px">lack of red blood cells<br />bleeding tendency</td></tr><tr><td style="width:112px">Immune system<br />disorders</td><td style="width:105px">&nbsp;</td><td style="width:96px">&nbsp;</td><td style="width:104px">hypersensitivity</td><td style="width:104px">serious allergic reaction<br />and shock</td></tr><tr><td style="width:112px">Psychiatric disorders</td><td style="width:105px">&nbsp;</td><td style="width:96px">&nbsp;</td><td style="width:104px">&nbsp;</td><td style="width:104px">anxiety<br />agitation<br />restlessness</td></tr><tr><td style="width:112px">Nervous system<br />disorders</td><td style="width:105px">&nbsp;</td><td style="width:96px">reduced<br />sense of<br />touch or<br />sensation</td><td style="width:104px">&nbsp;</td><td style="width:104px">dizziness<br />tingling feelings</td></tr><tr><td style="width:112px">Cardiac disorders</td><td style="width:105px">&nbsp;</td><td style="width:96px">&nbsp;</td><td style="width:104px">&nbsp;</td><td style="width:104px">failure of the heart<br />irregular heartbeats<br />increase in heart rate</td></tr><tr><td style="width:112px">Blood vessels and<br />circulatory disorders</td><td style="width:105px">&nbsp;</td><td style="width:96px">&nbsp;</td><td style="width:104px">&nbsp;</td><td style="width:104px">clot in blood vessels<br />drop in blood pressure<br />increase in blood<br />pressure<br />failure of the blood<br />circulation<br />reddening of the skin</td></tr><tr><td style="width:112px">Respiratory disorders</td><td style="width:105px">&nbsp;</td><td style="width:96px">lack of<br />oxygen</td><td style="width:104px">&nbsp;</td><td style="width:104px">respiratory failure<br />bleeding in the lungs<br />constriction of the<br />bronchi<br />fluid in the lungs<br />breathlessness<br />difficulty in breathing</td></tr><tr><td style="width:112px">Stomach and<br />intestines disorders</td><td style="width:105px">&nbsp;</td><td style="width:96px">vomiting<br />nausea</td><td style="width:104px">&nbsp;</td><td style="width:104px">abdominal pain</td></tr><tr><td style="width:112px">Skin disorders</td><td style="width:105px">hives<br />itching</td><td style="width:96px">&nbsp;</td><td style="width:104px">&nbsp;</td><td style="width:104px">rash<br />increased sweating</td></tr><tr><td style="width:112px">Muscular and<br />skeletal disorders</td><td style="width:105px">&nbsp;</td><td style="width:96px">&nbsp;</td><td style="width:104px">&nbsp;</td><td style="width:104px">back pain</td></tr><tr><td style="width:112px">General disorders<br />and administration<br />site conditions</td><td style="width:105px">&nbsp;</td><td style="width:96px">fever</td><td style="width:104px">&nbsp;</td><td style="width:104px">chest pain<br />chest discomfort<br />chills<br />localised swelling<br />general discomfort<br />application site reaction</td></tr><tr><td style="width:112px">nvestigations</td><td style="width:105px">&nbsp;</td><td style="width:96px">&nbsp;</td><td style="width:104px">&nbsp;</td><td style="width:104px">antibody test positive<br />oxygen in blood<br />decreased</td></tr><tr><td style="width:112px">Injury, poisoning<br />and procedural<br />complications</td><td style="width:105px">&nbsp;</td><td style="width:96px">&nbsp;</td><td style="width:104px">&nbsp;</td><td style="width:104px">increased blood volume<br />citrate poisoning<br />destruction of red blood<br />cells</td></tr></tbody></table><p>Depending on type and severity of adverse reactions, the infusion rate must be reduced or the<br />administration must be stopped. Appropriate action will be taken by your doctor.<br />If any of the side effects get serious, or if you notice any side effects not listed in this leaflet,<br />please tell your doctor.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.<br />Do not use this medicine after the expiry date which is stated on the label after the abbreviation<br />EXP.<br />Store and transport frozen (at &le; -18&deg;C).<br />Store in the original package in order to protect from light.<br />After thawing, chemical and physical in-use stability has been demonstrated for 5 days at<br />2-8&deg;C or 8 hours at room temperature (20-25&deg;C).<br />From a microbiological point of view, unless the method of opening precludes the risk of<br />microbial contamination, the product should be used immediately. If not used immediately,<br />in-use storage times and conditions are the responsibility of the user.<br />Do not use this medicine if you notice that the solution is cloudy or contains deposits and/or<br />discoloration.<br />Do not throw away any medicines via wastewater or household waste. Ask your pharmacist<br />how to throw away medicines you no longer use. These measures will help to protect the<br />environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- The active substances are ABO-blood group specific human plasma proteins. A 200 ml bag<br />contains 9 &ndash; 14 g (45 - 70 mg/mL).<br />- The other ingredients are:<br />Sodium citrate dihydrate, Sodium dihydrogenphosphate dihydrate and Glycine</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                octaplasLG is presented as a solution for infusion.
200 ml in bag.
Pack size of 1 and 10.
The frozen solution is (slightly) yellow.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder:</strong><br />Octapharma AG<br />Seidenstrasse 2<br />8853 Lachen<br />Switzerland<br /><strong>Manufacturers:</strong><br />Octapharma AB<br />SE-112 75 Stockholm<br />Sweden</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved in 01/2019
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="ltr">اوكتابلاس ال جي هي بلازما بشرية مجمعة ومعالجة لتعطيل الفيروسات. البلازما البشرية هي الجزء السائل<br />من الدم البشري الذي يحمل الخلايا، وهو يحتوي على بروتينات البلازما البشرية التي تعتبر مهمة للحفاظ على<br />خصائص التخثر الطبيعية ويتم استخدامها بنفس طريقة البلازما العادية الحيوية المجمدة.<br />يساعد اوكتابلاس ال جي في حالة النقص المعقد لعوامل التخثر والذي يمكن أن يحدث بسبب قصور شديد في<br />الكبد أو نقل الدم بشكل كبير. يمكن أيضًا إعطاء اوكتابلاس ال جي في حالات الطوارئ عندما يكون عامل تجلط<br />الدم (مثل العامل الخامس أو العامل 11 ) غير متوفر أو لم يكن التشخيص المخبري الضروري متوفر.<br />يمكن أيضاً أن يعطى بسرعة لعكس آثار مضادات التخثر الفموية (من نوع كومارين أو اندانيديون) عندما<br />غير كافي بسبب ضعف وظائف الكبد أو في حالات الطوارئ. K يكون فيتامين<br />يمكن إعطاء اوكتابلاس ال جي للمرضى الذين يخضعون لتغيير البلازما من أجل استعادة توازن عوامل التخثر.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="ltr">لا تستخدم اوكتابلاس ال جي:<br />- إذا كنت تعاني من حساسية لبروتينات البلازما البشرية أو أي من المكونات الأخرى لهذا الدواء (المذكورة<br />في القسم 6)<br />IgA - إذا كنت تعرف أن لديك أجسام مضادة ضد الغلوبيولين المناعي تسمى-<br />FFP - إذا حصلت لك ردود فعل سابقة تجاه أي شيء معد باستخدام البلازما البشرية أو-<br />(في الدم K وهو بروتين يعتمد على فيتامين )S&nbsp; إذا عرفت أن لديك مستوى منخفض من البروتين-<br /><strong>الاحتياطات والمحاذير</strong><br />تحدث إلى الطبيب قبل استخدام اوكتابلاس ال جي<br />أخبر طبيبك إذا كنت تعاني من أية أمراض أخرى<br /><strong>:ابذل عناية خاصة مع اوكتابلاس ال جي</strong><br />A إذا كان لديك مستوى منخفض من الغلوبولين المناعي-<br />FFP إذا ظهرت لديك ردود فعل سابقة تجاه بروتين البلازما بما في ذلك-<br />( إذا كنت تعاني من قصور القلب أو تراكم السوائل في الرئتين (الوذمة الرئوية-<br />&nbsp;إذا كنت تعاني من مخاطر الإصابة بمضاعفات تخثر الدم المعروفة بسبب احتمال زيادة خطر حدوث-<br />الجلطات الدموية الوريدية<br />( في حالة زيادة تثبيط التجلط (انحلال الفيبرين-.<br />.إن اوكتابلاس ال جي لا يوصى به عموماً لمعالجة مرض فون ويليبراند</p><p dir="ltr"><u>السلامة من الفيروس</u><br />عندما يتم تصنيع الأدوية من دم الإنسان أو البلازما، يتم وضع بعض التدابير لمنع انتقال العدوى إلى المرضى،<br />حيث تشمل تلك التدابير الاختيار الدقيق للمتبرعين بالدم والبلازما من أجل التأكد من استبعاد الأشخاص الحاملين<br />للأمراض مع فحص كل عينة تبرع ومجامع البلازما بحثًا عن علامات الإصابة بالفيروس أو العدوى. تحتوي<br />الشركات المصنعة لهذه المنتجات أيضًا خطوات لمعالجة الدم أو البلازما يمكنها تعطيل أو إزالة الفيروسات.<br />على الرغم من تلك التدابير، إلا أنه عندما يتم إعطاء الأدوية التي يتم إعدادها من دم بشري أو بلازما، لا يمكن<br />استبعاد احتمال انتقال العدوى تمامًا. ينطبق هذا أيضًا على أي فيروسات غير معروفة أو ناشئة أو أنواع أخرى<br />.من العدوى<br />B تعتبر التدابير المتخذة فعالة للفيروسات المغطاة مثل فيروس نقص المناعة البشرية وفيروس التهاب الكبد<br />وفيروس التهاب الكبد الوبائي. قد تكون التدابير المتخذة ذات قيمة محدودة ضد بعض الفيروسات غير المغلفة<br />.Parvovirus B وفيروس 19 E وفيروس التهاب الكبد A مثل فيروس التهاب الكبد<br />يوصى بشدة أن يتم في كل مرة تتلقى فيها جرعة من اوكتابلاس ال جي تسجيل اسم ورقم الدفعة للمنتج من<br />أجل الاحتفاظ بسجل للدفعات المستخدمة.<br />إذا تلقيت بشكل متكرر أو منظم B و A قد يوصي الطبيب باعتبار أخذ لقاح ضد فيروسات التهاب الكبد<br />منتجات مشتقة من البلازما البشرية.<br /><strong>الأطفال</strong><br />لا يوجد دراسات كافية على الأطفال<br /><strong>استخدام أدوية أخرى مع اوكتابلاس ال جي</strong><br />خلال التجارب السريرية، تم إعطاء اوكتابلاس ال جي مع أدوية أخرى مختلفة ولم يتم تحديد أي تفاعلات.<br />يفضل عدم خلط اوكتابلاس ال جي مع السوائل أو الأدوية الوريدية الأخرى باستثناء خلايا الدم الحمراء<br />والصفائح الدموية.<br />لتجنب احتمال حدوث جلطات دموية، يجب عدم إعطاء المحاليل التي تحتوي على الكالسيوم عن طريق نفس<br />المسار الوريدي الخاص ب اوكتابلاس ال جي.<br />لا توجد تفاعلات معروفة عند استخدام أدوية أخرى.<br />أخبر طبيبك إذا كنت تأخذ أو أخذت مؤخراً أية أدوية أخرى بما في ذلك التي يتم الحصول عليها دون وصفة<br />طبية.<br /><strong>أخذ اوكتابلاس ال جي مع الطعام والشراب</strong><br />.لم يتم ملاحظة أي تفاعلات</p><p dir="ltr"><strong>الحمل والرضاعة الطبيعية والخصوبة</strong><br />إذا كنت حاملاً أو ترضعين رضاعة طبيعية أو تعتقدين انك حامل أو تنوين الانجاب، اطلبي مشورة الطبيب قبل<br />أخذ هذا الدواء. سيتم إعطاؤك اوكتابلاس ال جي فقط إذا اعتبره الطبيب ضرورياً لحالتك.<br /><strong>القيادة وتشغيل الآلات</strong><br />لم يتم ملاحظة أية تأثيرات على القدرة على القيادة أو تشغيل الآلات. أنت وحدك المسؤول عن قرار ما إذا كنت<br />في وضع ملائم لقيادة مركبة أو تأدية مهام أخرى تتطلب زيادة التركيز.<br /><strong>معلومات هامة حول بعض مكونات اوكتابلاس ال جي</strong><br />. للحصول على قائمة المكونات يرجى الرجوع إلى القسم 6<br />يحتوي هذا الدواء على 920 مغ صوديوم كحد أقصى (المكون الرئيسي للطبخ / ملح الطعام) في كل كيس. هذا<br />يساوي كحد أقصى % 46 من حصة الحمية الغذائية اليومية الموصى بها من الصوديوم للشخص البالغ.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>سيتم إعطاء اوكتابلاس ال جي لك من قبل الطبيب أو الممرضة عن طريق الحقن في الوريد. تعتمد الجرعة<br />على وضعك السريري ووزنك، حيث سيحدد طبيبك الكمية المناسبة التي يجب أن تأخذها.<br />&nbsp;قبل إعطاء اوكتابلاس ال جي عن طريق الحقن يجب إجراء اختبار التوافق مع مجموعة فصيلة الدم ABO.<br />&nbsp;في الحالات الطارئة يمكن إعطاء مجموعة فصيلة الدم AB&nbsp;من اوكتابلاس ال جي لجميع المرضى.<br />من المهم ألا يزيد معدل التسريب عن 1 مل من اوكتابلاس ال جي لكل كغ من وزن الجسم في الدقيقة. يمكن<br />إعطاء غلوكونات الكالسيوم في وريد آخر لتقليل الآثار السلبية للسيترات الموجودة في اوكتابلاس ال جي.<br />يجب مراقبتك خلال 20 دقيقة على الأقل التي تلي أخذ الدواء في حالة تطور رد فعل تحسسي لديك أو صدمة،<br />وفي هذه الحالة يجب إيقاف الحقن فوراً.<br /><strong>في حال الحصول على اوكتابلاس ال جي أكثر مما يجب</strong><br />يمكن أن تؤدي الجرعات العالية إلى زيادة في السوائل, تراكم السوائل في الرئتين و/أو اضطرابات في القلب.<br /><strong>نسيان أخذ اوكتابلاس ال جي</strong><br />طبيبك هو المسؤول عن الإشراف على إعطائه والمحافظة على القيم المخبرية ضمن النطاق المحدد.<br /><strong>التوقف عن أخذ اوكتابلاس ال جي</strong><br />بناءً على القيم المخبرية سيقرر طبيبك متى يجب إيقاف إعطاء اوكتابلاس ال جي وسيقيم المخاطر المحتملة.<br />لا تستخدم المستحضر بعد تاريخ الانتهاء المحدد على العبوة.</p><p><strong>هناك عدة خيارات لتذويب اوكتابلاس ال جي المجمد:</strong><br />- حمام مائي<br />قم بالتذويب في الغلاف الخارجي لمدة لا تقل عن 30 دقيقة في حمام مائي بين + 30 إلى 37 + درجة<br />مئوية. يمكن استخدام حقيبة تغليف لتوفير المزيد من الحماية للمحتويات إذا كان ذلك مناسبًا.<br />قم بمنع الماء من تلويث منفذ الإدخال. الحد الأدنى من الوقت للذوبان هو 30 دقيقة عند 37 درجة مئوية.<br />يجب ألا تزيد درجة الحرارة في حمام الماء عن 37 + درجة مئوية ويجب ألا تقل عن 30 + درجة مئوية.<br />يعتمد وقت التذويب على عدد الأكياس في الحمام المائي. إذا تم إذابة المزيد من أكياس البلازما بشكل<br />متزامن يمكن إطالة زمن الذوبان ولكن لا ينبغي أن يكون أطول من 60 دقيقة.<br />- استخدام نظام نقع جاف مثل SAHARA-III<br />ضع أكياس اوكتابلاس ال جي على لوحة التحريك وفقاً لتعليمات الشركة المصنعة وقم بذويب البلازما<br />باستخدام وظيفة النقع السريع. عندما تظهر درجة حرارة + 37 درجة مئوية على شاشة عرض الحرارة قم<br />بإنهاء عملية النقع وإزالة الأكياس.<br />أثناء تذويب اوكتابلاس ال جي باستخدام نظام النقع الجاف يوصى باستخدام طابعة البروتوكول لتسجيل مسار<br />درجة حرارة مكونات الدم ورسائل الخطأ في حالة حدوث تعطل.<br />- أخرى<br />يمكن استخدام أنظمة تذويب أخرى لاوكتابلاس ال جي شريطة التحقق من صحة الطرق لهذا الغرض.<br />اسمح لمحتويات الحقيبة بأن تصبح دافئة إلى ما يقارب 37 + درجة مئوية قبل الحقن. يجب ألا تتجاوز درجة<br />حرارة اوكتابلاس ال جي 37 + درجة مئوية. أخرج الغلاف الخارجي وافحص الكيس بحثًا عن الشقوق أو<br />التسريبات.<br />تجنب رج الكيس.<br />بعد التذويب يكون المحلول خالياً من الجسيمات الصلبة أو الجيلاتينية ونقياً. لا تستخدم المحاليل التي تكون<br />معتمة أو تحتوي على رواسب و / أو تغير لونها. يجب عدم إعادة تجميد اوكتابلاس ال جي المذاب، ويجب<br />التخلص من المنتج غير المستخدم. يجب التخلص من أي منتج أو نفايات طبية غير مستخدمة وفقًا للمتطلبات<br />المحلية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية، يمكن أن يسبب هذا الدواء أعراضاً جانبية على الرغم من أنها قد لا تصيب الجميع. نادرًا<br />ما يمكن ملاحظة تفاعلات فرط الحساسية والتي عادةً ما تكون تفاعلات تحسسية معتدلة تتكون من إحمرار<br />موضعي أو عام للجلد أو طفح أو حكة. يمكن أن تكون الأشكال الأكثر حدة معقدة مثل الهبوط في ضغط الدم أو<br />تورم الوجه أو اللسان. قد يكون لردود الفعل التحسسية الشديدة في كامل الجسم بداية سريعة وقد تكون خطيرة.<br />تشمل الأعراض انخفاض في ضغط الدم ، وزيادة في معدل ضربات القلب ، وصعوبة في التنفس ، وصفير عند<br />التنفس ، والسعال ، وضيق التنفس ، والغثيان ، والتقيؤ ، والإسهال ، وآلام البطن أو الظهر. ردود الفعل الشديدة<br />قد تتطور إلى صدمة ، وفقدان الوعي ، وقصور الجهاز التنفسي ونادراً جداً قد تحدث الوفاة.<br />يمكن أن تحدث التأثيرات السلبية من السيترات الموجودة في اوكتابلاس ال جي ومستوى الكالسيوم المنخفض<br />ذو الصلة خاصة إذا كان معدل التسريب مرتفعًا أو إذا كان لديك اضطرابات في وظائف الكبد أو إذا كنت<br />تخضع لإجراءات تبادل البلازما. قد تعاني من أعراض مثل التعب، الشعور بالوخز (المذل) ، الرعاش<br />وانخفاض مستويات الكالسيوم.<br />يمكن أن يزيد اوكتابلاس ال جي من خطر تجلطات الدم في شرايين:<br />&bull; الأطراف، مما يسبب الألم والتورم في الأطراف<br />&bull; الرئتين مما يسبب ألم الصدر وعدم القدرة على التنفس<br />&bull; الدماغ مما يسبب الضعف و/او فقدان الإحساس في جانب واحد من الجسم<br />&bull; القلب مما يسبب ألم الصدر<br />بالنسبة لجميع المرضى المعرضين لخطر زيادة تخثر الدم يجب توخي الحذر بشكل خاص ويجب أخذ التدابير<br />المناسبة بعين الاعتبار.<br />إن عدم التوافق بين الأجسام المضادة في اوكتابلاس ال جي والمستضدات في الدم نادراً ما يمكن أن يؤدي إلى<br />تدمير خلايا الدم الحمراء )ردود فعل نقل الدم(. تشمل الأعراض القشعريرة والحمى والسعال وصعوبة في<br />التنفس وطفح جلدي ونزيف داخل الجسم.<br />قد يؤدي تسريب اوكتابلاس ال جي إلى ظهور أجسام مضادة لعوامل محددة للتخثر.<br />الجرعات العالية أو معدلات التسريب المرتفعة قد تحفز زيادة حجم الدم أو السوائل في الرئتين و / أو قصور<br />القلب.</p><p>أثناء التجارب السريرية مع المنتج السابق لاوكتابلاس ال جي واستخدامه بعد الموافقة، تم تحديد التأثيرات<br />الجانبية التالية:</p><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="1" cellpadding="1" style="width:585px"><tbody><tr><td style="width:115px"><strong>فئة العضو الجهازي</strong></td><td style="text-align:center; width:130px"><strong>شائعة<br />(&ge; 1/100<br />إلى<br />1/10 &gt; أو<br />1% &le; إلى &gt;<br />10%)</strong></td><td style="text-align:center; width:96px"><strong>غير شائعة<br />(&ge; 1/1,000<br />إلى<br />1/100 &gt; أو<br />0.1% &le; إلى &gt;<br />1%)</strong></td><td style="text-align:center; width:144px"><strong>نادرة<br />(&ge; 1/10,000<br />إلى<br />1/1,000 &gt; أو<br />0.01% &le; إلى &gt;<br />0.1%)</strong></td><td style="text-align:center; width:99px"><strong>نادرة جداً<br />1/10,000 &gt;) أو<br />&lt; 0.01%)</strong></td></tr><tr><td style="width:115px">اضطرابات جهاز الدم</td><td style="width:130px">&nbsp;</td><td style="width:96px">&nbsp;</td><td style="width:144px">&nbsp;</td><td style="width:99px">نقص خلايا الدم الحمراء<br />والميل للنزيف</td></tr><tr><td style="width:115px">اضطرابات الجهاز المناعي</td><td style="width:130px">&nbsp;</td><td style="width:96px">&nbsp;</td><td style="width:144px">فرط الحساسية</td><td style="width:99px">ردود الفعل التحسسية<br />الخطيرة والصدمة</td></tr><tr><td style="width:115px">الاضطرابات النفسية</td><td style="width:130px">&nbsp;</td><td style="width:96px">&nbsp;</td><td style="width:144px">&nbsp;</td><td style="width:99px">القلق<br />التهيج<br />عدم الراحة</td></tr><tr><td style="width:115px">اضطرابات الجهاز العصبي</td><td style="width:130px">&nbsp;</td><td style="width:96px">انخفاض<br />الإحساس باللمس</td><td style="width:144px">&nbsp;</td><td style="width:99px">الدوار<br />الشعور بالوخز</td></tr><tr><td style="width:115px">اضطرابات القلب</td><td style="width:130px">&nbsp;</td><td style="width:96px">&nbsp;</td><td style="width:144px">&nbsp;</td><td style="width:99px">قصور القلب<br />عدم انتظام ضربات القلب<br />زيادة معدل النبض</td></tr><tr><td style="width:115px">اضطرابات الدورة الدموية<br />والشرايين</td><td style="width:130px">&nbsp;</td><td style="width:96px">&nbsp;</td><td style="width:144px">&nbsp;</td><td style="width:99px"><p>تجلط الأوعية الدموية<br />انخفاض ضغط الدم</p><p>ارتفاع ضغط الدم<br />قصور الدورة الدموية<br />احمرار الجلد</p></td></tr><tr><td style="width:115px">اضطرابات الجهاز<br />التنفسي</td><td style="width:130px">&nbsp;</td><td style="width:96px">نقص الأكسجين</td><td style="width:144px">&nbsp;</td><td style="width:99px">قصور النفس<br />نزيف في الرئتين<br />انقباض الشعب الهوائية<br />تراكم سوائل في الرئتين<br />ضيق التنفس<br />صعوبة في التنفس</td></tr><tr><td style="width:115px">اضطرابات المعدة<br />والأمعاء</td><td style="width:130px">&nbsp;</td><td style="width:96px">قيء<br />غثيان</td><td style="width:144px">&nbsp;</td><td style="width:99px">ألم البطن</td></tr><tr><td style="width:115px">اضطرابات الجلد</td><td style="width:130px">شرى<br />حكة</td><td style="width:96px">&nbsp;</td><td style="width:144px">&nbsp;</td><td style="width:99px">الطفح<br />زيادة التعرق</td></tr><tr><td style="width:115px">اضطرابات العظام<br />والعضلات</td><td style="width:130px">&nbsp;</td><td style="width:96px">&nbsp;</td><td style="width:144px">&nbsp;</td><td style="width:99px">ألم في الظهر</td></tr><tr><td style="width:115px">الاضطرابات العامة<br />وظروف موضع الإعطاء</td><td style="width:130px">&nbsp;</td><td style="width:96px">حمى</td><td style="width:144px">&nbsp;</td><td style="width:99px">ألم الصدر<br />رعشة<br />عدم راحة عامة<br />ردود فعل في موضع<br />التسريب</td></tr><tr><td style="width:115px">التحقيقات</td><td style="width:130px">&nbsp;</td><td style="width:96px">&nbsp;</td><td style="width:144px">&nbsp;</td><td style="width:99px">نتيجة إيجابية في فحص<br />الأجسام المضادة<br />انخفاض الأكسجين في<br />الدم</td></tr><tr><td style="width:115px">الإصابات والتسمم<br />والمضاعفات الإجرائية</td><td style="width:130px">&nbsp;</td><td style="width:96px">&nbsp;</td><td style="width:144px">&nbsp;</td><td style="width:99px">زيادة حجم الدم<br />تسمم السيترات<br />تدمير خلايا الدم الحمراء</td></tr></tbody></table><p>بالاعتماد على نوع وشدة ردود الفعل يجب تقليل التسريب أو إيقافه. سيتم اتخاذ الإجراء الملائم من قبل الطبيب.<br />في حال أصبحت أي من الأعراض الجانبية خطيرة أو لاحظت أية أعراض جانبية غير مدرجة في هذه النشرة<br />يرجى ابلاغ الطبيب.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>إحفظ هذا الدواء بعيدا عن متناول الأطفال.<br />لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العلبة الخارجية.<br />يحفظ وينقل مجمداً بدرجة &ge; 18 - مئوية<br />يحفظ بالعبوة الأصلية لحمايته من الضوء<br />&ndash; بعد التذويب يظهر الاستقرار الكيميائي والفيزيائي المستخدم لمدة 5 أيام بدرجة 2-8 مئوية او 8 ساعات&nbsp;<br />&nbsp;بدرجة حرارة الغرفة ( 20- 25 مئوية)&nbsp;<br />من وجهة نظر ميكروبيولوجية، ما لم تمنع طريقة الفتح خطر التلوث الميكروبي؛ يجب أن يتم استخدام المنتج<br />على الفور. إن لم يتم استخدامه على الفور فإن أوقات وظروف التخزين عند الاستخدام تعتبر من مسؤولية<br />المستخدم.<br />لا تستخدم هذا الدواء إذا لاحظت أن المحلول معتم أو يحتوي على شوائب و/او متغير اللون.<br />لا تتخلص من الأدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص<br />من الأدوية التي لم تعد بحاجة اليها. ستساعد هذه التدابير على حماية البيئة.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>-&nbsp;المادة الفعالة هي بروتينات بلازما بشرية مخصصة بفصيلة الدم ABO. يحتوي &nbsp;كيس 200 مل على 9-14 غرام (45-70 مغ/مل)</p><p>-المحتويات الأخرى تشمل:<br />سيترات ثنائي هيدرات الصوديوم ، ثنائي هيدرات ثنائي هيدروجين فوسفات الصوديوم والجليسين</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>يتوفر اوكتابلاس ال جي على شكل محلول للحقن.<br />200 مل للكيس<br />حجم العبوة 1 و 10<br />لون المحلول المجمد مائل للاصفرار</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>حامل رخصة التسويق</strong><br />اوكتافارما ايه جي<br />سايدينستراشي 2<br />8853 لاشين<br />سويسرا</p><p><strong>المصنّع</strong><br />اوكتافارما ايه بي<br />75 ستوكهولم اس اي &ndash; 112<br />السويد</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
             تمت مراجعة هذه النشرة في 01/2019
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                octaplasLG, solution for infusion.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                A 200 ml bag contains 9 - 14 g of ABO-blood group specific human plasma proteins (45 - 70 mg/mL). octaplasLG is supplied in separate presentations according to the following blood groups: 
Blood group A
Blood group B
Blood group AB
Blood group O
For details about important coagulation factors and inhibitors, see section 5.1 and table 2.
For the full list of excipients, see section 6.1.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for infusion.
The frozen solution is (slightly) yellow.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Complex deficiencies of coagulation factors such as coagulopathy due to severe hepatic failure or massive transfusion.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Substitution therapy in coagulation factor deficiencies, when a specific coagulation factor concentrate (e.g. factor V or factor XI) is not available for use or in emergency situations when a precise laboratory diagnosis is not possible.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rapid reversal of the effects of oral anticoagulants (coumarin or indanedione type), when a prothrombin complex concentrate is not available for use or administration of vitamin K is insufficient due to impaired liver function or in emergency situations.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Potentially dangerous haemorrhages during fibrinolytic therapy, using e.g. tissue plasminogen activators, in patients who fail to respond to conventional measures.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Therapeutic plasma exchange procedures, including those in thrombotic thrombocytopenic purpura (TTP).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The dosage depends upon the clinical situation and underlying disorder, but 12-15 ml octaplasLG/kg body weight is a generally accepted starting dose. This should increase the patient&#39;s plasma coagulation factor levels by approximately 25%.</p><p>It is important to monitor the response, both clinically and with measurement of e.g. activated partial thromboplastin time (aPTT), prothrombin time (PT), and/or specific coagulation factor assays.</p><p>Dosage for coagulation factor deficiencies:</p><p>An adequate haemostatic effect in minor and moderate haemorrhages or surgery in coagulation factor deficient patients is normally achieved after the infusion of 5-20 mL octaplasLG/kg body weight. This should increase the patient&#39;s plasma coagulation factor levels by approximately 10-33 %. In the event of major haemorrhage or surgery, the expert advice of a haematologist should be sought.</p><p>Dosage for TTP and haemorrhages in intensive plasma exchange:</p><p>For therapeutic plasma exchange procedures, the expert advice of a haematologist should be sought.</p><p>In TTP patients the whole plasma volume exchanged should be replaced with octaplasLG.</p><p><strong>Method of administration</strong></p><p>Administration of octaplasLG must be based on ABO-blood group specificity. In emergency cases, octaplasLG blood group AB can be regarded as universal plasma since it can be given to all patients regardless of blood group.</p><p>octaplasLG must be administered by intravenous infusion after thawing, as described in section 6.6, using an infusion set with a filter. An aseptic technique must be used throughout the infusion.</p><p>After thawing the solution is clear to slightly opalescent and free of solid or gelatinous particles.</p><p>Due to the risk of citrate toxicity, the infusion rate should not exceed 0.020-0.025 mmol citrate/kg body mass/minute - equal to &pound;1 ml octaplasLG/kg body mass/minute. Toxic effects of citrate can be minimised by giving calcium gluconate intravenously into another vein.</p><p>&nbsp;</p><p><strong><em>Paediatric population</em></strong></p><p>The efficacy and safety of octaplasLG have not been evaluated in pediatric patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                -	IgA deficiency with documented antibodies against IgA
-	Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 or residues from the manufacturing process, as stated in section 5.3.
-	Severe deficiencies of protein S

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>octaplasLG should not be used:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; As a volume expander.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In cases of bleeding caused by coagulation factor deficiencies where a specific factor concentrate is available for use.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; To correct hyperfibrinolysis in liver transplantation or other conditions with complex disturbances of haemostasis caused by a deficiency of plasmin inhibitor, also named a<sub>2</sub>-antiplasmin.</p><p><strong>octaplasLG should be used with caution under the following conditions:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; IgA deficiency.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Plasma protein allergy.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Previous reactions to fresh-frozen plasma (FFP) or octaplasLG.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Manifest or latent cardiac decompensation.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pulmonary oedema.</p><p>In order to reduce the risk for venous thromboembolism caused by the reduced protein S activity of octaplasLG compared to normal plasma (see section 5.1), caution should be exercised and appropriate measures should be considered in all patients at risk for thrombotic complications.</p><p>In intensive plasma exchange procedures, octaplasLG should only be used to correct the coagulation abnormality when abnormal haemorrhage occurs.</p><p><strong>Viral safety</strong></p><p>Standard measures to prevent infections resulting from the use of medical products prepared from human blood or plasma include selection of donors, screening of individual donations and plasma pool for specific markers of infection and the inclusion of effective manufacturing steps for the inactivation/removal of viruses. Despite this, when medicinal products prepared from human blood or plasma are administered, the possibility of transmitting infective agents cannot be totally excluded. This also applies to unknown and emerging viruses and other pathogens.</p><p>The measures taken are considered effective for enveloped viruses such as HIV, HBV, and HCV. The measures taken may be of limited value against non-enveloped virus such as HAV, HEV and Parvovirus B19.</p><p>Parvovirus B19 infection may be serious for pregnant woman (fetal infection) and for individuals with immunodeficiency or increased erythropoiesis (e.g. haemolytic anaemia). HEV may also seriously affect seronegative pregnant women. Therefore octaplasLG should only be administered to these patients if strongly indicated.</p><p>Appropriate vaccination (e.g. against HBV and HAV) for patients in regular receipt of medicinal products derived from human blood or plasma should be considered.</p><p>Additionally, a step to remove prions is incorporated.</p><p>It is strongly recommended that every time that octaplasLG is administered to a patient, the name and batch number of the product are recorded in order to maintain a link between the patient and the batch of the product.</p><p><strong>Blood group-specific administration</strong></p><p>Administration of octaplasLG must be based on ABO-blood group specificity. In emergency cases, octaplasLG blood group AB can be regarded as universal plasma since it can be given to all patients regardless of blood group.</p><p>Patients should be observed for at least 20 minutes after the administration.</p><p><strong>Anaphylactic reactions</strong></p><p>In case of anaphylactic reaction or shock, the infusion must be stopped immediately. Treatment should follow the guidelines for shock therapy.</p><p><strong>Paediatric population</strong></p><p>Data on the use of octaplasLG in paediatric patients is limited, therefore, the product should only be administered to these individuals if the likely benefits clearly outweigh potential risks.</p><p>&nbsp;</p><p>This medicinal product contains maximum 920 mg sodium per bag, equivalent to maximum 46% of the WHO recommended maximum daily intake of 2 g sodium for an adult.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Interactions:</strong></p><p>No interactions with other drugs have been identified.</p><p><strong>Incompatibilities:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; octaplasLG<sup> </sup>product can be mixed with red blood cells and platelets if ABO compatibility of both preparations is respected.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; octaplasLG must not be mixed with other medicinal products, as inactivation and precipitation may occur.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; To avoid the possibility of clot formation, solutions containing calcium must not be administered by the same intravenous line as octaplasLG.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The safety of octaplasLG for use in human pregnancy has not been established in controlled clinical trials. It is not known whether octaplasLG can affect reproduction capacity. The product should be administered to a pregnant or lactating woman only if alternative therapies are regarded inappropriate.</p><p>For potential risk of Parvovirus B19 and HEV transmission, see section 4.4.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>After ambulant infusion, the patient should rest for one hour.</p><p>octaplasLG has no or negligible influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Hypersensitivity reactions may rarely be observed. These are usually mild allergic type reactions consisting of localised or generalised urticaria, erythema, flushing and pruritus. More severe forms can be complicated by hypotension or angioedema of the face or larynx. If other organ systems &ndash; cardiovascular, respiratory or gastrointestinal &ndash; are involved, the reaction would be considered anaphylactic or anaphylactoid. Anaphylactic reactions may have a rapid onset and may be serious; the symptom complex may include hypotension, tachycardia, bronchospasm, wheezing, coughing, dyspnoea, nausea, vomiting, diarrhoea, abdominal or back pain. Severe reactions may proceed to shock, syncope, respiratory failure and very rarely even death.</p><p>High infusion rates may rarely cause cardiovascular effects as a result of citrate toxicity (fall in ionised calcium), especially in patients with liver function disorders. In the course of plasma exchange procedures, symptoms attributable to citrate toxicity such as fatigue, paraesthesia, tremor, and hypocalcemia may be observed rarely.</p><p>&nbsp;</p><p>During clinical trials with octaplasLG&rsquo;s predecessor product, and its post-approval use, the following adverse reactions have been identified:</p><p>&nbsp;</p><p>Frequencies have been evaluated according to the following convention: very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000), not known (cannot be estimated from the available data).</p><p><strong>Table 1: Adverse reactions that have been identified for octaplasLG</strong></p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td style="vertical-align:top"><p><strong>System organ class*</strong></p></td><td style="vertical-align:top"><p><strong>Common<br />(</strong><strong>&ge;</strong><strong> 1/100 to<br />&lt; 1/10 or</strong><br /><strong>&ge; 1% to &lt; 10%</strong><strong>)</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon<br />(</strong><strong>&ge;</strong><strong> 1/1,000 to<br />&lt; 1/100 or</strong><br /><strong>&ge; 0.1% to &lt; 1%</strong><strong>)</strong></p></td><td style="vertical-align:top"><p><strong>Rare<br />(</strong><strong>&ge;</strong><strong> 1/10,000 to<br />&lt; 1/1,000 or</strong><br /><strong>&ge; 0.01% to &lt; 0.1%</strong><strong>)</strong></p></td><td style="vertical-align:top"><p><strong>Very Rare<br />(&lt; 1/10,000 or<br />&lt; 0.01%)</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>haemolytic anaemia<br />haemorrhagic diathesis</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>anaphylactoid reaction</p></td><td style="vertical-align:top"><p>hypersensitivity</p></td><td style="vertical-align:top"><p>anaphylactic shock<br />anaphylactic reaction</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>anxiety<br />agitation<br />restlessness</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>hypoaesthesia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>dizziness<br />paraesthesia</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>cardiac arrest<br />arrhythmia<br />tachycardia</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>thromboembolism (LLT)<br />hypotension<br />hypertension<br />circulatory collapse<br />flushing</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>hypoxia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>respiratory failure<br />pulmonary haemorrhage<br />bronchspasm<br />pulmonary oedema<br />dyspnoea<br />respiratory disorder</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>vomiting<br />nausea</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>abdominal pain</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>urticaria<br />pruritus</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>rash (erythematous)<br />hyperhidrosis</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>back pain</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>pyrexia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>chest pain<br />chest discomfort<br />chills<br />localised oedema<br />malaise<br />application site reaction</p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>antibody test positive<br />oxygen saturation decreased</p></td></tr><tr><td style="vertical-align:top"><p>Injury, poisoning and procedural complications</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>transfusion-related circulatory overload<br />citrate toxicity<br />haemolytic transfusion reaction</p></td></tr></tbody></table><p>*This table contains MedDRA Preferred Terms (PTs) unless indicated otherwise.</p><p>LLT, MedDRA Lowest Level Term</p><p><strong>To report any side effect(s):</strong></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Saudi Arabia:</em></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>o&nbsp;&nbsp; Fax: +966-11-205-7662</p><p>o&nbsp;&nbsp; Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340</p><p>o&nbsp;&nbsp; Toll free phone: 8002490000</p><p>o&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>o&nbsp;&nbsp; Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Other GCC states:</em></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; High dosages or infusion rates may induce hypervolaemia/circulatory overload, pulmonary oedema and/or cardiac failure.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; High infusion rates may cause cardiovascular effects as a result of citrate toxicity (fall in ionised calcium), especially in patients with liver function disorders.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Blood substitutes and plasma protein fractions,<br />ATC code: B05A A.</p><p>The content and distribution of plasma proteins in octaplasLG remain in the final product at comparable levels to those in the raw material FFP, i.e. 45-70 mg/mL, and the major plasma proteins are all within the reference ranges for healthy blood donors (see table 2). Out of a mean total protein content of 58 mg/ml, albumin accounts for 50% (29 mg/ml), whereas the immunoglobulin classes G, A, and M are present at levels of 8.1, 1.6, and 0.8 mg/ml, respectively. As a result of the S/D treatment and purification, the content in lipids and lipoproteins is reduced. This is of no relevance within the indications for octaplasLG.</p><p>The manufacturing process levels out inter-donor variations and maintain the plasma proteins in a functional state. Therefore, octaplasLG possesses the same clinical activity as the average single-donor FFP unit, but is more standardised. The finished product is tested for coagulation factors V, VIII, and XI, and the inhibitors protein C, protein S, and plasmin inhibitor. A minimum of 0.5 IU/mL is obtained for each of the three coagulation factors, whereas the inhibitor levels are guaranteed equal or higher than 0.7, 0.3, and 0.2 IU/mL. The fibrinogen content is between 1.5 and 4.0 mg/mL. In routine production, all clinically important parameters are within the 2.5-97.5 percentiles reference range for single-donor FFP, except plasmin inhibitor (also known as a<sub>2</sub>-antiplasmin) that is just below (see table 2). octaplasLG displays the same von Willebrand factor multimeric pattern as normal plasma.</p><p><strong>Table 2: Global coagulation parameters and specific coagulation factors and inhibitors in octaplasLG</strong></p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td><p><strong>Parameter</strong></p></td><td><p><strong>octaplasLG<br />Mean &plusmn; standard deviation<br />(n = 5)</strong></p></td><td><p><strong>Reference<br />range*</strong></p></td></tr></thead><tbody><tr><td><p>Activated partial thromboplastin time [sec]</p></td><td><p>30 &plusmn; 1</p></td><td><p>28-41</p></td></tr><tr><td><p>Prothrombin time [sec]</p></td><td><p>11 &plusmn; 0</p></td><td><p>10-14**</p></td></tr><tr><td><p>Fibrinogen [mg/mL]</p></td><td><p>2.6 &plusmn; 0.1</p></td><td><p>1.5-4.0**</p></td></tr><tr><td><p>Coagulation factor II [IU/mL]</p></td><td><p>1.01 &plusmn; 0.07</p></td><td><p>0.65-1.54</p></td></tr><tr><td><p>Coagulation factor V [IU/mL]</p></td><td><p>0.76 &plusmn; 0.05</p></td><td><p>0.54-1.45</p></td></tr><tr><td><p>Coagulation factor VII [IU/mL]</p></td><td><p>1.09 &plusmn; 0.05</p></td><td><p>0.62-1.65</p></td></tr><tr><td><p>Coagulation factor VIII [IU/mL]</p></td><td><p>0.80 &plusmn; 0.07</p></td><td><p>0.45-1.68</p></td></tr><tr><td><p>Coagulation factor IX [IU/mL]</p></td><td><p>0.88 &plusmn; 0.10</p></td><td><p>0.45-1.48</p></td></tr><tr><td><p>Coagulation factor X [IU/mL]</p></td><td><p>0.99 &plusmn; 0.05</p></td><td><p>0.68-1.48</p></td></tr><tr><td><p>Coagulation factor XI [IU/mL]</p></td><td><p>0.88 &plusmn; 0.04</p></td><td><p>0.42-1.44</p></td></tr><tr><td><p>Coagulation factor XII [IU/mL]</p></td><td><p>1.04 &plusmn; 0.08</p></td><td><p>0.40-1.52</p></td></tr><tr><td><p>Coagulation factor XIII [IU/mL]</p></td><td><p>1.03 &plusmn; 0.06</p></td><td><p>0.65-1.65</p></td></tr><tr><td><p>Antithrombin [IU/mL]</p></td><td><p>0.86 &plusmn; 0.11</p></td><td><p>0.72-1.45</p></td></tr><tr><td><p>Heparin cofactor II [IU/mL]</p></td><td><p>1.12 &plusmn; 0.05</p></td><td><p>0.65-1.35</p></td></tr><tr><td><p>Protein C [IU/mL]</p></td><td><p>0.86 &plusmn; 0.08</p></td><td><p>0.58-1.64</p></td></tr><tr><td><p>Protein S [IU/mL]</p></td><td><p>0.63 &plusmn; 0.08</p></td><td><p>0.56-1.68</p></td></tr><tr><td><p>Von Willebrand factor ristocetin cofactor activity [IU/mL]</p></td><td><p>0.93 &plusmn; 0.08</p></td><td><p>0.45-1.75</p></td></tr><tr><td><p>ADAMTS13<sup>#</sup> activity [IU/mL]</p></td><td><p>1.13 &plusmn; 0.17</p></td><td><p>0.50-1.10**</p></td></tr><tr><td><p>Plasminogen [IU/mL]</p></td><td><p>0.84 &plusmn; 0.06</p></td><td><p>0.68-1.44</p></td></tr><tr><td><p>Plasmin inhibitor<sup>##</sup> [IU/mL]</p></td><td><p>0.61 &plusmn; 0.04</p></td><td><p>0.72-1.32</p></td></tr></tbody></table><p>*According [[1],[2]] based on the testing of 100 healthy blood donors and defined by the 2.5 and 97.5 percentiles; or **according package insert of test kit.</p><p><sup>#</sup>A disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13. Also known as von Willebrand factor-cleaving protease (VWFCP).</p><p><sup>##</sup>Also known as a<sub>2</sub>-antiplasmin.</p><p>&nbsp;</p><p>[[1]] Hellstern P, Sachse H, Schwinn H, Oberfrank K. Manufacture and characterization of a solvent/detergent-treated human plasma. Vox Sang 1992; 63:178-185</p><p>[[2]] Beeck H, Hellstern P. In vitro characterization of solvent/detergent-treated human plasma and of quarantine fresh frozen plasma. Vox Sang 1998; 74 (Suppl. I):219-223</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>octaplasLG has similar pharmacokinetic properties as FFP</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Virus inactivation is carried out using Tri (N-Butyl) Phosphate (TNBP) and Octoxynol (Triton X-100). These S/D reagents are removed during the purification process. The maximum amounts of TNBP and Octoxynol in the finished product are &lt; 2 &micro;g/ml and &lt; 5 &micro;g/ml, respectively.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sodium citrate dihydrate 0.88 - 1.48 g /200ml bag</p><p>Sodium dihydrogenphosphate dihydrate0.06 - 0.24 g/ 200ml bag</p><p>Glycine 0.80 - 1.20 g/200 ml bag</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; octaplasLG<sup> </sup>product can be mixed with red blood cells and platelets if ABO compatibility of both preparations is respected.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; octaplasLG must not be mixed with other medicinal products, as inactivation and precipitation may occur.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; To avoid the possibility of clot formation, solutions containing calcium must not be administered by the same intravenous line as octaplasLG.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                4 years.
After thawing, chemical and physical in-use stability has been demonstrated for 5 days at 2-8°C or 8 hours at room temperature (20-25°C).
From a microbiological point of view, unless the method of opening precludes the risk of microbial contamination, the product should be used immediately. If not used immediately, in-use storage times and conditions are the responsibility of the user.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store and transport frozen (at &le; -18&deg;C).</p><p>Store in the original package in order to protect from light</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>200 ml of ABO-blood group specific human plasma proteins in bag (polyvinyl chloride) over-wrapped with a film.</p><p>Pack size of 1 and 10.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;Do not use after the expiry date given on the label.</p><p><strong>There are several options for thawing frozen octaplasLG:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Water bath:</p><p>Thaw in the outer wrapper for not less than 30 minutes in a circulating water bath at +30&deg;C to +37&deg;C. An overwrap bag may be used to provide further protection of contents if appropriate.</p><p>Prevent water from contaminating the entry port. The minimum thawing time is 30 minutes at 37&deg;C. Temperature in the water bath must never exceed +37 &deg;C and should not be lower than +30 &deg;C.</p><p>The thawing time depends on the number of bags in the water bath. If more plasma bags are thawed in parallel, the thawing time can be prolonged, but should not be longer than 60 minutes.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Using a dry tempering system such as the SAHARA-III:</p><p>Place the octaplasLG bags on the agitation plate according to the manufacturer instructions and thaw plasma using the fast tempering function. When a +37&deg;C blood component temperature is indicated on the temperature display, terminate the tempering process and remove the bags.<br />During thawing of octaplasLG using a dry tempering system, it is recommended to use the protocol printer to record the course of the blood component temperature and error messages in event of failure.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Others:</p><p>Other thawing systems for frozen octaplasLG can be used on the condition that the methods are validated for that purpose.</p><p>Allow the content of the bag to warm to approximately +37 &deg;C before infusion. The temperature of octaplasLG must not exceed +37 &deg;C. Remove the outer wrapper and examine the bag for cracks or leaks.</p><p>Avoid shaking.</p><p>After thawing the solution is clear to slightly opalescent and free of solid or gelatinous particles.</p><p>Do not use solutions which are cloudy or have deposits and/or discoloration.</p><p>Thawed octaplasLG must not be refrozen. Unused product must be discarded.</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Octapharma AG
Seidenstrasse 2
8853 Lachen
Switzerland

MANUFACTURER(S)
Octapharma AB
112 75 Stockholm
Sweden


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                01/2018
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>